Evidence map›Paper›PMID 38556870›Full record

ArticleJournal of translational medicine2024

Very low-calorie ketogenic diet (VLCKD): a therapeutic nutritional tool for acne?

Ludovica Verde, Evelyn Frias-Toral, Sara Cacciapuoti, Daniel Simancas-Racines, Matteo Megna, Giuseppina Caiazzo, Luca Potestio, Maria Maisto, Gian Carlo Tenore, Annamaria Colao and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ludovica Verde *Department of Public Health, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.
Evelyn Frias-Toral *School of Medicine, Universidad Espíritu Santo, Samborondón, 0901952, Ecuador.
Sara Cacciapuoti *Section of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Daniel Simancas-RacinesCentro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, 170129, Ecuador. dsimancas@ute.edu.ec.ORCID 0000-0002-3641-1501
Matteo MegnaSection of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Giuseppina CaiazzoDipartimento di Scienze Biomediche avanzate, Università Degli Studi Di Napoli Federico II, Naples, Italy.
Luca PotestioSection of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Maria MaistoDepartment of Pharmacy, University of Naples "Federico II", Naples, Italy.
Gian Carlo TenoreDepartment of Pharmacy, University of Naples "Federico II", Naples, Italy.
Annamaria ColaoCentro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O), Unità di Endocrinologia, Diabetologia e Andrologia, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.
Silvia SavastanoCentro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O), Unità di Endocrinologia, Diabetologia e Andrologia, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.
Giovanna Muscogiuri *Centro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O), Unità di Endocrinologia, Diabetologia e Andrologia, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.
Luigi Barrea *Centro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O), Unità di Endocrinologia, Diabetologia e Andrologia, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.ORCID 0000-0001-9054-456X
University of Naples Federico II · ITPegaso University · ITUniversidad de Especialidades Espíritu Santo · ECUniversidad UTE · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcne, a chronic inflammatory disease impacting the pilosebaceous unit, is influenced significantly by inflammation and oxidative stress, and is commonly associated with obesity. Similarly, obesity is also associated with increased inflammation and oxidation. The role of diet in acne remains inconclusive, but the very low-calorie ketogenic diet (VLCKD), known for weight loss and generating anti-inflammatory ketone bodies, presents promising potential. Despite this, the effects of VLCKD on acne remain underexplored. This study aimed to investigate the efficacy of a 45-day active phase of VLCKD in reducing the clinical severity of acne in young women with treatment-naïve moderate acne and grade I obesity.

methodsThirty-one women with treatment-naïve moderate acne, grade I obesity (BMI 30.03-34.65 kg/m

resultsVLCKD resulted in general improvements in anthropometric and body composition parameters. Significantly, there were significant reductions in both the GAGS score (Δ%: - 31.46 ± 9.53, p < 0.001) and the DLQI score (Δ%: - 45.44 ± 24.02, p < 0.001) after the intervention. These improvements coincided with significant decreases in TMAO (p < 0.001) and dROMs (p < 0.001) levels and a significant increase in PhA (Δ%: + 8.60 ± 7.40, p < 0.001). Changes in the GAGS score positively correlated with changes in dROMs (p < 0.001) and negatively with PhA (p < 0.001) even after adjusting for Δ% FM. Changes in the DLQI score positively correlated with changes in dROMs (p < 0.001) and negatively with PhA (p < 0.001) even after adjustment for Δ% FM.

conclusionGiven the side effects of drugs used for acne, there is an increasing need for safe, tolerable, and low-cost treatments that can be used for acne disease. The 45-day active phase of VLCKD demonstrated notable improvements in acne severity, and these improvements seemed to be attributable to the known antioxidant and anti-inflammatory effects of VLCKD.

Indexed as

Acne VulgarisDiet, KetogenicMethylaminesAnti-Inflammatory AgentsFemaleHumansInflammationObesityAnti-Inflammatory AgentsMethylaminestrimethyloxamineAcneDietInflammationKetogenic dietNutritionObesityOxidative stressVery low-calorie ketogenic dietVLCKD

Identifiers

PMID38556870
PMCPMC10983624
OpenAlexW4393357140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.